Dec 26, 2025 • DC News Now
BEARISH
Fraud Investigation: Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Shareholders
Levi & Korsinsky has launched an investigation into Iovance Biotherapeutics, Inc. (IOVA) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after Iovance reported lower-than-expected Q1 2025 results and slashed its full-year revenue guidance. The company attributed the poor performance to manufacturing facility maintenance and lower Proleukin sales.
Dec 24, 2025 • Sahm
SOMEWHAT-BULLISH
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge?
Iovance Biotherapeutics Inc. (IOVA) is strengthening its position through new employee stock options and renewed optimism for its Amtagvi cell therapy and broader pipeline. This combination of talent incentives and improving sentiment around tumor-infiltrating lymphocyte (TIL) therapies, including potential expansion into non-small cell lung cancer, is positively influencing the company's long-term prospects. However, investors should be aware of the company's high cash burn and dependence on Amtagvi's commercial scaling amidst ongoing losses.
Dec 23, 2025 • ts2.tech
BULLISH
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)
Iovance Biotherapeutics (NASDAQ: IOVA) saw a significant stock jump on December 22, 2025, driven by a Barclays price target increase and high short interest. The article details positive analyst sentiment, routine corporate updates, and the fundamental story centered around Amtagvi's commercial scaling, margin improvement, and promising pipeline developments for 2026. However, it also highlights risks associated with commercial execution, financing, and dilution, crucial for a clinical-stage biotech.
Dec 23, 2025 • MarketBeat
NEUTRAL
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?
Iovance Biotherapeutics (NASDAQ:IOVA) saw its shares rise by 8.7% on Monday, closing at $2.6950 with a significant drop in trading volume. Despite this surge, analysts are divided on the company's prospects, with a consensus "Hold" rating and an average price target of $11.10. The clinical-stage biotech, which focuses on tumor-infiltrating lymphocyte (TIL) therapies, continues to report negative earnings and margins while institutional investors have been actively adjusting their positions.
Dec 23, 2025 • StocksToTrade
SOMEWHAT-BULLISH
Iovance Biotherapeutics: Is it Time to Invest?
Iovance Biotherapeutics (NASDAQ: IOVA) stocks recently surged by 9.48% due to FDA designations and promising results, leading Barclays to increase its price target for the company to $10 with an Overweight rating. Despite current operating losses, strategic investments, a strong current ratio, and stock options for new employees suggest a potential for future growth and a positive shift in financial performance. The article emphasizes disciplined, data-driven trading decisions over emotional ones when considering investment in volatile markets.
Dec 20, 2025 • MarketBeat
NEUTRAL
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC
Squarepoint Ops LLC significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 115.2% in Q2, bringing its total to 856,569 shares valued at $1.47 million. While analysts have a "Hold" consensus rating with an average target price of $11.10, the company recently reported an EPS beat but missed revenue expectations, remaining unprofitable. Iovance Biotherapeutics is a clinical-stage biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) immunotherapies.